DataMeds AI, Inc. MEDS
in 2022, we are a holding company for existing and future planned operating companies centered around pharmaceuticals and healthcare
services. We seek to be a micro health ecosystem, with a portfolio of companies consisting of a pharmacy, wholesale operations, and a
technology division that provides a novel platform for hub and clinical services. We are focused on improving the lives of patients while
delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. With the successful integration of its
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $23.3M | $18.1M | — | — |
| Cost of revenue | $29.8M | $16.4M | — | — |
| Gross profit | -$6.4M | $1.8M | — | — |
| SG&A | $70.3M | $6.8M | $2.9M | — |
| Total operating expenses | $87.3M | $7.9M | $2.9M | — |
| Operating income | -$93.7M | -$6.1M | -$2.9M | — |
| Interest expense | $4.6M | $831.5K | $15.1K | — |
| Pre-tax income | -$101.3M | -$6.9M | -$2.9M | — |
| Net income | -$101.3M | -$6.9M | -$2.9M | — |
| EPS, basic | -1.43 | -0.15 | -0.06 | — |
| EPS, diluted | -1.43 | -0.15 | -0.06 | — |
| Shares, diluted (wtd. avg.) | $71.0M | $47.3M | $44.7M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | $42.6K | $1.0M | $1.4K | — |
| Inventory | $1.6M | $9.5M | — | — |
| Total current assets | $2.8M | $15.2M | $338.4K | — |
| Property, plant and equipment | $229.4K | $388.2K | — | — |
| Goodwill | $14.2M | $16.2M | — | — |
| Other intangibles | $2.5M | $1.6M | — | — |
| Total assets | $30.5M | $57.3M | $338.4K | — |
| Short-term debt | $10.9M | $11.9M | $350.0K | — |
| Total current liabilities | $29.8M | $38.0M | $2.9M | — |
| Long-term debt | $12.6M | $11.5M | — | — |
| Total liabilities | $42.9M | $50.6M | $3.2M | — |
| Retained earnings | -$111.0M | -$9.8M | -$2.9M | — |
| Total equity | -$12.4M | $6.7M | -$2.9M | -$5.2K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | -$10.9M | -$1.2M | -$349.1K | — |
| Depreciation and amortisation | $158.8K | $67.6K | — | — |
| Stock-based compensation | $200.0K | $1.1M | — | — |
| Investing cash flow | -$881.5K | $469.1K | — | — |
| Financing cash flow | $10.8M | $1.8M | $350.5K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-018958.
Others in SIC 5122
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| MCK | MCKESSON CORP | $105.86B | 23.7x | 12.4% |
| COR | Cencora, Inc. | $63.15B | 41.6x | 9.3% |
| CAH | CARDINAL HEALTH INC | $57.49B | 34.2x | 14.2% |
| HLF | HERBALIFE LTD. | $1.30B | 5.6x | 0.9% |
| NUS | NU SKIN ENTERPRISES, INC. | $235.6M | 1.5x | -14.3% |
| COSM | Cosmos Health Inc. | $27.5M | — | 19.9% |
| HWH | HWH International Inc. | $14.5M | — | -30.8% |
| HKPD | Cellyan Biotechnology Co., Ltd | — | — | — |